The Deane HBI, of the Icahn School of Medicine at Mount Sinai, will integrate transformative clinical and translational research programs. This groundbreaking and enduring program will enable Mount Sinai patients to participate in research, allowing Mount Sinai researchers to explore how the brain changes with age. We perform both clinical and translational research.
Clinical Research
At Mount Sinai, our seamless approach to the integration of clinical care and research ensures that patients have access to today’s newest and most promising cognitive therapies in the form of advanced clinical trials. Mount Sinai’s Alzheimer’s Disease Research Center (ADRC) is a comprehensive research facility and clinical program dedicated to the study and treatment of both normal aging and dementia. Physician-scientists at the ADRC conduct pioneering clinical research that aims to improve diagnosis, delay progression, and enhance the well-being of those with memory loss, in addition to helping us learn more about healthy cognition. Our clinicians and scientists partner with patients to make transformational changes in cognitive treatment at every level.
Clinical Trials
Through our collaborations with research centers at Mount Sinai, such as the Alzheimer’s Disease Research Center, we give our patients access to the newest and most promising therapies in the form of clinical trials. As part of The Friedman Brain Institute, we are active in research programs seeking to discover the underlying causes of cognitive and related neuropsychiatric disorders.
Translational Research
Translational research is research specifically designed to improve health outcomes, applying knowledge from basic biology and clinical trials to techniques and tools that address critical medical needs. Our multidisciplinary team of translational scientists is dedicated to investigating the underlying mechanisms of memory loss in both those suffering from cognitive decline and those experiencing normal cognitive changes associated with aging. With the state-of-the-art resources available within The Friedman Brain Institute, we conduct innovative translational research that will revolutionize the way we treat cognitive decline.